Edition:
United Kingdom

Gensight Biologics SA (SIGHT.PA)

SIGHT.PA on Paris Stock Exchange

1.54EUR
16 May 2019
Change (% chg)

-- (--)
Prev Close
€1.54
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
287,163
52-wk High
€5.28
52-wk Low
€1.34

Latest Key Developments (Source: Significant Developments)

Gensight Biologics Reports Positive 96-Week Data From Reverse Phase III Clinical Trial Of GS010
Wednesday, 15 May 2019 

May 15 (Reuters) - GENSIGHT BIOLOGICS SA ::GENSIGHT BIOLOGICS REPORTS POSITIVE 96-WEEK DATA FROM REVERSE PHASE III CLINICAL TRIAL OF GS010 FOR THE TREATMENT OF LEBER HEREDITARY OPTIC NEUROPATHY (LHON).BILATERAL IMPROVEMENT CONTINUES IN KEY VISUAL FUNCTIONS BCVA AND CONTRAST SENSITIVITY.GS010 SAFETY AND TOLERABILITY ESTABLISHED OVER COURSE OF TRIAL.RESPONDER ANALYSES SUGGEST IMPROVED CLINICAL OUTCOMES FOR GS010-TREATED EYES RELATIVE TO SHAM-TREATED EYES.BRIEFING PACKAGES INCORPORATING FINDINGS UNDER PREPARATION FOR MEETINGS WITH REGULATORY AUTHORITIES.  Full Article

Gensight Biologics Announces Positive Data On Gs030
Tuesday, 7 May 2019 

May 7 (Reuters) - GENSIGHT BIOLOGICS SA ::GENSIGHT BIOLOGICS ANNOUNCES POSITIVE DATA SAFETY MONITORING BOARD REVIEW AND CONTINUATION OF PIONEER PHASE I/II CLINICAL TRIAL OF GS030 COMBINING GENE THERAPY AND OPTOGENETICS FOR THE TREATMENT OF RETINITIS PIGMENTOSA.GENSIGHT EXPECTS TO COMPLETE ENROLLMENT IN FIRST HALF OF 2020.EARLY FINDINGS MAY BE AVAILABLE AND RELEASED IN SECOND HALF OF 2019.PRELIMINARY RESULTS ARE EXPECTED IN Q4 OF 2020.  Full Article

Gensight Biologics Reports Positive Follow-Up Results Of Phase III Clinical Trial Of Gs010
Wednesday, 17 Apr 2019 

April 17 (Reuters) - GENSIGHT BIOLOGICS SA ::GENSIGHT BIOLOGICS REPORTS POSITIVE FOLLOW-UP RESULTS AT WEEK 72 OF THE RESCUE PHASE III CLINICAL TRIAL OF GS010 IN LEBER HEREDITARY OPTIC NEUROPATHY (LHON).GENSIGHT BIOLOGICS REPORTS POSITIVE FOLLOW-UP RESULTS AT WEEK 72 OF RESCUE PHASE III CLINICAL TRIAL OF GS010 IN LEBER HEREDITARY OPTIC NEUROPATHY.GS010 CONTINUED TO BE SAFE AND WELL-TOLERATED THROUGH 72 WEEKS.GS010-TREATED EYES SHOWED CONTINUOUS RECOVERY OF VISUAL FUNCTIONS FROM NADIR IN BEST-CORRECTED VISUAL ACUITY, CONTRAST SENSITIVITY.  Full Article

Gensight Biologics Cash And Cash Equivalents Of 26.2 Million Euros As Of End-Dec.
Wednesday, 23 Jan 2019 

Jan 23 (Reuters) - GENSIGHT BIOLOGICS SA ::GENSIGHT BIOLOGICS REPORTS ITS CASH POSITION AS OF DECEMBER 31, 2018.GENSIGHT BIOLOGICS' CASH AND CASH EQUIVALENTS WAS EUR 26.2 MILLION AS OF DECEMBER 31, 2018.CASH AND CASH EQUIVALENTS WAS €26.2 MILLION AS OF DECEMBER 31, 2018, COMPARED TO €39.2 MILLION AS OF SEPTEMBER 30, 2018.ACCELERATION OF CASH BURN IN LAST QUARTER OF 2018 PRINCIPALLY REFLECTS FINAL STEPS OF PHARMACEUTICAL DEVELOPMENT FOR GS010.FOR GS010, IN PREPARATION FOR A MARKETING AUTHORIZATION FILING IN EUROPE; THIS FILING IS EXPECTED IN LAST QUARTER OF 2019.  Full Article

Gensight Biologics End Of September Cash And Cash Equivalents Down At 39.2 Million Euros
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - GENSIGHT BIOLOGICS SA ::GENSIGHT BIOLOGICS REPORTS ITS CASH POSITION AS OF SEPTEMBER 30, 2018.CASH AND CASH EQUIVALENTS WAS EUR 39.2 MILLION AS OF SEPTEMBER 30, 2018, COMPARED TO EUR 41.7 MILLION AS OF JUNE 30, 2018..  Full Article

Gensight Biologics cash position slightly dips, issues update on GS010
Wednesday, 25 Apr 2018 

April 25 (Reuters) - Gensight Biologics SA ::* GenSight Biologics’ cash and cash equivalents amounted to €49.2 million as of March 31, 2018, compared to €55.4 million as of December 31, 2017.* On April 3, 2018, GenSight Biologics reported the topline results from REVERSE Phase III clinical trial of GS010 in patients with Leber Hereditary Optic Neuropathy (LHON)..* At 48 weeks, the study demonstrated clinically meaningful improvement of +11 ETDRS letters in GS010-treated eyes and similar improvement in sham-treated eyes across the 37 subjects enrolled, suggesting an unexpected bilateral treatment effect.* In addition, SD-OCT demonstrated statistically significant relative preservation of both retinal ganglion cell volume and nerve fiber layer thickness in treated eyes while untreated eyes continued to deteriorate.* Following these topline results, GenSight Biologics is further investigating the full set of data, as well as running multiple post hoc analyses, to better understand the observed treatment effect and responder profiles.  Full Article

Gensight Biologics FY Net Loss Widens to 24.1 Million Euros
Wednesday, 28 Feb 2018 

Feb 28 (Reuters) - GENSIGHT BIOLOGICS SA ::FY NET LOSS EUR 24.1 MILLION VERSUS LOSS OF EUR 22.1 MILLION YEAR AGO.FY OPERATING LOSS EUR 24.0 MILLION VERSUS LOSS OF EUR 22.0 MILLION YEAR AGO.FY OPERATING REVENUE EUR 3.7 MILLION VERSUS EUR 3.0 MILLION YEAR AGO.  Full Article

Gensight Biologics Reports Positive Results From Phase I/Ii Study Of Gs010
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - GENSIGHT BIOLOGICS SA ::GENSIGHT BIOLOGICS REPORTS POSITIVE LONG-TERM VISUAL ACUITY GAINS AND SAFETY RESULTS FROM PHASE I/II STUDY OF GS010 FOR THE TREATMENT OF LEBER HEREDITARY OPTIC NEUROPATHY (LHON).CONFIRMATION OF THE FAVORABLE LONG-TERM SAFETY PROFILE OF GS010‍​.SIGNIFICANT IMPROVEMENT OF VISUAL ACUITY AT 2.5 YEARS OF FOLLOW-UP IN CERTAIN LHON PATIENTS.LHON PATIENTS WITH LESS THAN 2 YEARS OF ONSET OF VISUAL LOSS PRIOR TO TREATMENT.  Full Article

Gensight Biologics: cash and cash equivalents position at Sept 30 at EUR 59.5​ million
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - GENSIGHT BIOLOGICS SA : :‍CASH AND CASH EQUIVALENTS AMOUNTED TO EUR 59.5 MILLION AS OF SEPTEMBER 30, 2017, COMPARED TO EUR 63.6 MILLION AS OF JUNE 30, 2017.​.  Full Article

Gensight Biologics appoints Barrett Katz as Chief Medical Officer
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - GENSIGHT BIOLOGICS SA ::GENSIGHT BIOLOGICS APPOINTS BARRETT KATZ AS CHIEF MEDICAL OFFICER.  Full Article